Compare Virgin Galactic Holdings, Inc. (SPCE) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Virgin Galactic Holdings, Inc. vs Twist Bioscience Corp — how do they compare? Virgin Galactic Holdings, Inc. trades at $2.76 (market cap $329.06M), while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: Twist Bioscience Corp is far larger — about 16.6× Virgin Galactic Holdings, Inc.'s market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Virgin Galactic Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| SPCE | TWST | |
|---|---|---|
Market Cap | $329.06M | $5.45B |
Sector | Industrials | Health |
52-Week High | $7.52 | $102.88 |
52-Week Low | $2.17 | $24.16 |
Enterprise Value | $428.90M | $5.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPCE trades at $2.78, up 8.59% in the last session, but remains in a bearish technical trend with negative cash flows and deep losses. The company reported a net loss of $278.91 million on minimal revenue of $1.54 million in 2025, with profitability metrics deeply negative. Recent news highlights volatility tied to space sector sentiment and SpaceX's market activities, contributing to sharp price swings.
The outlook is highly speculative with significant execution and funding risks. While analyst ratings are mixed, the lack of revenue scale and persistent cash burn pose substantial challenges. Investment potential hinges on successful commercialization, but current fundamentals do not support a sustainable valuation, making it suitable only for high-risk investors.
TWST trades at $95.86, up 2.14% today, with a bullish technical signal and strong institutional interest. Revenue growth is robust, rising from $204M in 2022 to $377M in 2025, though the company remains unprofitable with a net income margin of -19.85%. Recent news highlights AI-driven collaborations and earnings beats, but cash flow trends show persistent operational losses.
The outlook is mixed; analyst consensus is bullish with a $91.63 price target, but profitability challenges and negative cash flows pose significant risks. Investment opportunity lies in continued revenue expansion and AI partnerships, while execution risks and high valuations require caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
